Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2

Journal of Medicinal Chemistry

Volumn 54, Issue 2, 2011, Pages 580-590

  Caldwell, John J ^a,c   Welsh, Emma J ^a   Matijssen, Cornelis ^a   Anderson, Victoria E ^a   Antoni, Laurent ^a   Boxall, Kathy ^a   Urban, Frederique ^a   Hayes, Angela ^a   Raynaud, Florence I ^a   Rigoreau, Laurent J M ^b   Raynham, Tony ^b   Aherne, G Wynne ^a   Pearl, Laurence H ^a   Oliver, Antony W ^a   Garrett, Michelle D ^a   Collins, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 FLUORO 2 [4( 4 (2 HYDROXYPROPAN 2 YL)PYRROLIDIN 3 YLAMINO) 6,7 DIMETHOXYQUINAZOLIN 2 YL]PHENOL; CCT 241533; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; PHENOL DERIVATIVE; POTASSIUM CHANNEL HERG; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CELL STRAIN HT29; COLON CANCER; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; RADIATION PROTECTION; STRUCTURE ACTIVITY RELATION; THYMOCYTE;

ANIMALS; APOPTOSIS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HT29 CELLS; HUMANS; MICE; MODELS, MOLECULAR; PHENOLS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RADIATION-PROTECTIVE AGENTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THYMUS GLAND;

EID: 78751660013     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101150b     Document Type: Article

References (47)

1. Lengauer, C.; Kinzler, K. W.; Vogelstein, B. Genetic Instabilities in Human Cancers Nature 1998, 396, 643-649
2. Coleman, W. B.; Tsongalis, G. J. The Role of Genomic Instability in Human Carcinogenesis Anticancer Res. 1999, 19, 4645-4664
3. Reinhardt, H.; Yaffe, M. Kinases that Control the Cell Cycle Response to DNA damage: Chk1, Chk2, and MK2 Curr. Opin. Cell Biol. 2009, 21, 245-255
4. Samuel, T.; Weber, H.; Funk, J. Linking DNA Damage to Cell Cycle Checkpoints Cell Cycle 2002, 2, 162-168
5. Stracker, T. H.; Usui, T.; Petrini, J. H. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response DNA Repair 2009, 8, 1047-1054
6. Antoni, L.; Sodha, N.; Collins, I.; Garrett, M. D. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nature Rev. Cancer 2007, 7, 925-936
7. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer Nature 2004, 432, 316-323
8. Bartek, J.; Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer Cancer Cell 2003, 3, 421-429
9. Hirao, A.; Kong, Y.; Matsuoka, S.; Wakeman, A.; Ruland, J.; Yoshida, H.; Liu, D.; Elledge, S.; Mak, T. DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2 Science 2000, 287, 1824-1827
10. Ahn, J. Y.; Schwarz, J. K.; Piwnica-Worms, H.; Canman, C. E. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain Cancer Res. 2000, 60, 5934-5936
11. Matsuoka, S.; Rotman, G.; Ogawa, A.; Shiloh, Y.; Tamai, K.; Elledge, S. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 10389-10394
12. Ahn, J.; Li, X.; Davis, H. L.; Canman, C. E. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain J. Biol. Chem. 2002, 277, 19389-19395
13. Oliver, A. W.; Paul, A.; Boxall, K. J.; Barrie, S. E.; Aherne, G. W.; Garrett, M. D.; Mittnacht, S.; Pearl, L. H. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange EMBO J. 2006, 25, 3179-3190
14. Wu, X.; Chen, J. Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis J. Biol. Chem. 2003, 278, 36163-36168
15. Schwarz, J. K.; Lovly, C. M.; Piwnica-Worms, H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation Mol. Cancer Res. 2003, 1, 598-609
16. Pommier, Y.; Sordet, O.; Rao, V. A.; Zhang, H.; Kohn, K. W. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale Curr. Pharm. Des. 2005, 11, 2855-2872
17. Pommier, Y.; Weinstein, J. N.; Aladjem, M. I.; Kohn, K. W. Chk2 molecular interaction map and rationale for Chk2 inhibitors Clin. Cancer Res. 2006, 12, 2657-2661
18. Arienti, K. L.; Brunmark, A.; Axe, F. U.; McClure, K.; Lee, A.; Blevitt, J.; Neff, D. K.; Huang, L.; Crawford, S.; Pandit, C. R.; Karlsson, L.; Breitenbucher, J. G. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles J. Med. Chem. 2005, 48, 1873-1885
19. McClure, K. J.; Huang, L.; Arienti, K. L.; Axe, F. U.; Brunmark, A.; Blevitt, J.; Breitenbucher, J. G. Novel non-benzimidazole chk2 kinase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 1924-1928
20. Carlessi, L.; Buscemi, G.; Larson, G.; Hong, Z.; Wu, J. Z.; Delia, D. Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2 Mol. Cancer Ther. 2007, 6, 935-944
21. Larson, G.; Yan, S.; Chen, H.; Rong, F.; Hong, Z.; Wu, J. Z. Identification of novel, selective and potent Chk2 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 172-175
22. Jobson, A. G.; Cardellina, J. H.; Scudiero, D.; Kondapaka, S.; Zhang, H.; Kim, H.; Shoemaker, R.; Pommier, Y. Identification of a Bis-guanylhydrazone [4,4′-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase Mol. Pharmacol. 2007, 72, 876-884
23. Hilton, S.; Naud, S.; Caldwell, J. J.; Boxall, K.; Burns, S.; Anderson, V. E.; Antoni, L.; Allen, C. E.; Pearl, L. H.; Oliver, A. W.; Aherne, G. W.; Garrett, M. D.; Collins, I. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2 Bioorg. Med. Chem. 2010, 18, 707-718
24. Levesque, A.; Eastman, A. p53-Based Cancer Therapies: Is Defective p53 the Achilles Heel of the tumor? Carcinogenesis 2007, 28, 13-20
25. Kruse, J-. P.; Gu, W. Modes of p53 Regulation Cell 2009, 137, 609-622
26. Takai, H.; Naka, K.; Okada, Y.; Watanabe, M.; Harada, N.; Saito, S.; Anderson, C. W.; Appella, E.; Nakanishi, M.; Suzuki, H.; Nagashima, K.; Sawa, H.; Ikeda, K.; Motoyama, N. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription EMBO J. 2002, 21, 5195-5205
27. Jobson, A. G.; Lountos, G. T.; Lorenzi, P. L.; Llamas, J.; Connelly, J.; Cerna, D.; Tropea, J. E.; Onda, A.; Zoppoli, G.; Kondapaka, S.; Zhang, G.; Caplen, N. J.; Cardellina, J. H.; Yoo, S. S.; Monks, A.; Self, C.; Waugh, D. S.; Shoemaker, R. H.; Pommier, Y. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1 H -indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]- phenyl}-amide] J. Pharmacol. Exp. Ther. 2009, 331, 816-826
28. Raynham, T. M.; Hammonds, T. R.; Gilliatt, J. H.; Charles, M. D.; Pave, G. A.; Foxton, C. H.; Carr, J. L.; Mistry, N. S. Aminoethylamino-aryl (AEAA) compounds as PKD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of PKD-mediated diseases. PCT Int. Appl. WO2007125331, 2007.
29. Collins, I.; Caldwell, J. J.; Oliver, A. W.; Raynham, T. M.; Welsh, E. J.; Matijssen, C. A. Preparation of oxy-phenyl-aryl compounds as CHK2 kinase inhibitors for treating proliferative disorders and for radioprotection. PCT Int. Appl. WO2009053694, 2009.
30. Harikumar, K. B.; Kunnumakkara, A. B.; Ochi, N.; Tong, Z.; Deorukhkar, A.; Sung, B.; Kelland, L.; Jamieson, S.; Sutherland, R.; Raynham, T.; Charles, M.; Bagherazadeh, A.; Foxton, C.; Boakes, A.; Farooq, M.; Maru, D.; Diagaradjane, P.; Matsuo, Y.; Sinnett-Smith, J.; Gelovani, J.; Krishnan, S.; Aggarwal, B. B.; Rozengurt, E.; Ireson, C. R.; Guha, S. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo Mol. Cancer Ther. 2010, 9, 1136-1146
31. Ion Channel CardiacProfiler; Millipore Corporation: Billerica, MA; http://www.millipore.com/drugdiscovery/dd3/ionchannelprofiler.
32. Wilson, D.; Fanning, L. T. D.; Krenitsky, P.; Termin, A.; Joshi, P.; Sheth, U. Quinazolines useful as modulators of voltage gated ion channels and their preparation, pharmaceutical compositions and use in the treatment of diseases. PCT Int. Appl. WO2007058989, 2007.
33. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: highlights and hang-ups J. Med. Chem. 2006, 49, 5029-5046
34. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliand, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242
35. DeLano, W. L. The PyMOL Molecular Graphics System, 2009.
36. The National Centre for Protein Kinase Profiling, MRC Protein Phosphorylation Unit, Dundee University; http://www.kinase-screen.mrc.ac.uk/
37. Graczyk, P. P. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases J. Med. Chem. 2007, 50, 5773-5779
38. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes J. Med. Chem. 1998, 41, 1007-1010
39. Di, L.; Kerns, E. H.; Hong, Y.; Kleintop, T. A.; McConnell, O. J.; Huryn, D. M. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates J. Biomol. Screening 2003, 8, 453-462
40. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 1990, 82, 1107-1112
41. Workman, P.; Collins, I. Probing the probes: fitness factors for small molecule tools Chem. Biol. 2010, 17, 561-577
42. Simpson, G. L.; Gordon, A. H.; Lindsay, D. M.; Promsawan, N.; Crump, M. P.; Mulholland, K.; Hayter, B. R.; Gallagher, T. Glycosylated Foldamers to Probe the Carbohydrate-Carbohydrate Interaction J. Am. Chem. Soc. 2006, 128, 10638-10639
43. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV J. Med. Chem. 2007, 50, 2297-2300
44. Potterson, L.; McNicholas, S.; Krissinel, E.; Gruber, J.; Cowtan, K.; Emsley, P.; Murshudov, G. N.; Cohen, S.; Perrakis, A.; Noble, M. Developments in the CCP4Molecular-Graphics Project Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2288-2294
45. McCabe, N.; Turner, N. C.; Lord, C. J.; Kluzek, K.; Bialkowska, A.; Swift, S.; Giavara, S.; OConnor, M. J.; Tutt, A. N.; Zdzienicka, M. Z.; Smith, G. C. M.; Ashworth, A. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res. 2006, 66, 8109-8115
46. Anderson, V. E.; Walton, M. I.; Eve, P. D.; Caldwell, J. J.; Pearl, L. H.; Oliver, A. W.; Collins, I.; Garrett., M. D. CCT241533 is a potent and selective inhibitor of CHK2 which potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2010; 70, manuscript accepted for publication.
47. Matthews, T. P.; McHardy, T.; Klair, S.; Boxall, K.; Fisher, M.; Cherry, M.; Allen, C. E.; Addison, G. J.; Ellard, J.; Aherne, G. W.; Westwood, I. M.; van Montfort, R.; Garrett, M. D.; Reader, J. C.; Collins, I. Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2- a ]pyrazines as inhibitors of checkpoint and other kinases Bioorg. Med. Chem. Lett. 2010, 20, 4045-4049